Eli Lilly's ZEPBOUND (tirzepatide) emerges as a paradigm-shifting therapeutic breakthrough, revolutionizing contemporary approaches to sleep-related respiratory disorders. The pivotal FDA approves ZEPBOUND for obstructive sleep apnea decision in December 2024 introduces the first targeted pharmaceutical solution specifically engineered for addressing this complex sleep disorder. This...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Bangla